These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
62332-0679 Market Analysis and Financial Projection
The NDC code 62332-0679 corresponds to Ivabradine Hydrochloride Tablets, a cardiovascular drug primarily used to treat chronic heart failure and angina. Below is a detailed market analysis and price projection based on available data:
Market Analysis
Current Market Landscape
2023 Valuation: The Ivabradine Hydrochloride Tablets market was valued at $1.18 billion in 2022, with projections reaching $1.85 billion by 2030 at a 5.7% CAGR [10]. Another report estimates a broader market size of $9.5 billion in 2023, growing to $12.28 billion by 2030 at a 3.8% CAGR, driven by rising cardiovascular disease prevalence and aging populations [14].
Key Segments:
Dosage Strengths: 5 mg/tablet and 7.5 mg/tablet [12].
Applications: Hospitals (largest share), retail pharmacies, and clinics [12][14].
Regions: North America dominates due to high treatment adoption, while Asia-Pacific shows the fastest growth due to improving healthcare infrastructure [10][12].
Competitive Landscape
Major Players: Les Laboratoires Servier, Shandong New Time Pharmaceutical, Cadiasun Pharma, and Natco Pharma [12][14].
Market Drivers:
Increasing incidence of heart failure and angina.
Cost-effectiveness in reducing hospitalizations ($0.04 PMPM savings in Medicare plans) [13].
Expansion into emerging markets like China and India [10].
Price Trends and Projections
Current Pricing
Wholesale Acquisition Cost: $4,500 annually per patient in the U.S., with potential 20% reductions under negotiated discounts [13].
Cost-Effectiveness: Despite higher upfront costs, ivabradine reduces heart failure hospitalizations by 18–26%, leading to long-term savings ($991,256/year in commercial populations) [13][15].
Future Projections (2025–2030)
Factor
Impact on Pricing
Patent Expirations
Generic entries post-2030 may lower prices by 30–50% [10][14].
Demand Growth
Steady 5–6% annual price increases in branded formulations due to limited competition [10].
Regional Dynamics
North America: Prices remain high ($5,000–$6,000/year) due to reimbursement policies.
Asia-Pacific: Generic adoption could reduce costs to $1,200–$1,800/year by 2030 [12][14].
Key Challenges
Cost-Effectiveness Thresholds: In markets like Thailand, ivabradine’s ICER of $6,515/QALY exceeds local thresholds, limiting adoption [15].
Supply Chain Stability: Dependence on reactors like the University of Missouri for isotopes poses risks [5].
Strategic Recommendations
For Manufacturers: Focus on emerging markets with tiered pricing models to address affordability.
For Payers: Leverage ivabradine’s hospitalization cost savings ($37,507 per HF admission avoided) to justify formulary inclusion [13].
For Investors: Target companies with robust R&D in cardiovascular therapies, such as Servier and Natco Pharma [12][14].
“Ivabradine’s ability to reduce heart rate without affecting blood pressure positions it as a cornerstone in heart failure management.” – Journal of the American Heart Association [11].
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
